Next Article in Journal
Development and Characterization of Transcription Factor Gene-Derived Microsatellite (TFGM) Markers in Medicago truncatula and Their Transferability in Leguminous and Non-Leguminous Species
Next Article in Special Issue
Glutathione Levels and Susceptibility to Chemically Induced Injury in Two Human Prostate Cancer Cell Lines
Previous Article in Journal
Characterization of Melanogenesis Inhibitory Constituents of Morus alba Leaves and Optimization of Extraction Conditions Using Response Surface Methodology
Previous Article in Special Issue
Cysteine Specific Targeting of the Functionally Distinct Peroxiredoxin and Glutaredoxin Proteins by the Investigational Disulfide BNP7787
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Glutathione in Cellular Redox Homeostasis: Association with the Excitatory Amino Acid Carrier 1 (EAAC1)

*
Author to whom correspondence should be addressed.
Department of Pharmacology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi, Tokyo 173-8605, Japan
Submission received: 12 March 2015 / Accepted: 11 May 2015 / Published: 14 May 2015
(This article belongs to the Special Issue Thioredoxin and Glutathione Systems)

Abstract

:
Reactive oxygen species (ROS) are by-products of the cellular metabolism of oxygen consumption, produced mainly in the mitochondria. ROS are known to be highly reactive ions or free radicals containing oxygen that impair redox homeostasis and cellular functions, leading to cell death. Under physiological conditions, a variety of antioxidant systems scavenge ROS to maintain the intracellular redox homeostasis and normal cellular functions. This review focuses on the antioxidant system’s roles in maintaining redox homeostasis. Especially, glutathione (GSH) is the most important thiol-containing molecule, as it functions as a redox buffer, antioxidant, and enzyme cofactor against oxidative stress. In the brain, dysfunction of GSH synthesis leading to GSH depletion exacerbates oxidative stress, which is linked to a pathogenesis of aging-related neurodegenerative diseases. Excitatory amino acid carrier 1 (EAAC1) plays a pivotal role in neuronal GSH synthesis. The regulatory mechanism of EAAC1 is also discussed.

1. Introduction

More than 50 years ago, the “free radical theory of aging” suggested that endogenous oxygen radicals generated in cells were a risk factor for aging-related diseases, and a thiol compound such as cysteine was expected to slow the aging process [1]. Subsequent studies have shown the importance of disequilibrium in cellular reduction-oxidation status, called “redox” status, as a cause of oxidative stress [2]. Accumulated insults from oxidative stress damage cellular functions, especially in vulnerable tissues. In the present review, we focus on the regulation of cellular redox homeostasis especially in the central nervous system (CNS).

2. Glutathione as a Redox Buffer

Thiols, also called sulfhydryls, play pivotal roles in cellular redox homeostasis. There are four thiol-containing amino acids—cysteine, methionine, homocysteine, and taurine—but cysteine and methionine are the major thiol-containing amino acids involved in cellular metabolism in mammals [3]. Glutathione (GSH) is a cysteine-containing tripeptide, which is the most abundant nonprotein thiol in cells [4]. GSH is composed of glutamate, cysteine, and glycine and is synthesized intracellularly via two reactions catalyzed by γ-glutamylcysteine ligase (GCL) and GSH synthetase (GS) [5,6]. The reaction of glutamate with cysteine is catalyzed by GCL to produce a dipeptide, γ-glutamylcysteine, which then reacts with glycine catalyzed by GS to produce GSH. In this process, cysteine, but not glutamate or glycine, is the rate-limiting substrate because intracellular concentrations of both glutamate and glycine are higher than those of the Km values of the reactions [6]. GSH is present abundantly in the cells at millimolar concentrations in the liver > kidney > spleen > small intestine > brain > pancreas > lung > heart > muscle [7]. In the liver, kidney, intestine, and pancreas, cysteine is also supplied via the transsulfuration pathway, which converts methionine through homocysteine to cysteine [3,8].
GSH is considered the main redox buffer in a cell because of the large amount of reducing equivalents supplied by GSH [9]. The sulfhydryl residues of GSH molecules are easily oxidized to form GSH disulfide (GSSG), which is then reduced back to GSH by the reaction with GSH reductase (GR). The intracellular thiol redox status is described as the ratio of reduced to oxidized forms, GSH/GSSG, showing 100 or more at the steady state but decreasing to 10 or less under oxidative stress conditions [10,11]. Intracellular redox changes affect cell signaling, gene transcription, gene translation, cell proliferation, and cell death [12,13,14,15,16]. Proteins contain abundant sulfhydryl residues derived from their cysteine side-chains, which comprises up to 3% of the total amino acids in human [17]. Residues of cysteine, as well as those of methionine, tryptophan, and tyrosine, are prone to oxidative modification. Oxidation in the intracellular redox environment induces irreversible protein thiol oxidation and thereby alters protein functions as enzymes, receptors, and transporters [18]. Under oxidative stress conditions, GSH can reversibly form mixed disulfide bonds between protein thiols (S-glutathionylation) to prevent protein oxidation [19].
The redox state is more oxidative in the endoplasmic reticulum (ER) than in the cytosol; the GSH/GSSG ratio in the ER ranges from 1 to 3 [20]. This ratio is preferable for the folding of disulfide bond-containing proteins in the ER [20,21]. An initial observation suggested that the ER preferentially transports GSSG rather than GSH into the lumen in order to establish an oxidative environment [20]. However, subsequent studies showed the selective transport of GSH across the ER membrane [22,23]. Indeed, less than 50% of total GSH (GSH + GSSG) was free in the ER, while the remainder was found as mixed disulfides with proteins [21]. Although the significance of the low GSH/GSSG ratio is still elusive, protein disulfide formation with GSH in the ER might play an important role in protecting protein functions against oxidative stress.

3. Antioxidant Defense System

The human brain requires ~20% of the oxygen consumed by the body, even though it occupies only 2% of body weight. It contains high levels of unsaturated fatty acids, which would be targets for oxidative stress, but relatively low levels of antioxidants and related enzymes [5]. Reactive oxygen species (ROS) are endogenously produced from mitochondria, cytochrome P450 metabolism, peroxisomes, and inflammatory cell activation [24,25,26]. Notably, mitochondria generate ATP from ADP as a cellular energy molecule via oxidative phosphorylation. Oxidative phosphorylation is coupled with an electron transport chain, also known as a respiratory chain, on the mitochondrial inner membrane to pump protons out of the matrix and into the intermembrane space. This electrical proton gradient generates proton-motive force to synthesize ATP. During electron transfer through the respiratory chain, mitochondria generate large portions of ROS, such as superoxide, hydroxyl radical, hydroperoxyl radical, and hydrogen peroxide (H2O2), into the matrix and the intermembrane space. Previous reports have suggested that 2% of the total oxygen consumption in the mitochondrial respiratory chain produces superoxide generating H2O2 [27]. However, a recent study showed that only about 0.15% of electron flow in mitochondria is converted to H2O2 under resting conditions [28]. Although the steady state concentration of superoxide is approximately 5- to 10-fold higher in the mitochondrial matrix than in the cytosol and the nucleus [29], the steady state concentrations of mitochondrial superoxide and H2O2 are estimated to be as low as about 10−10 M and 10−9~10−8 M, respectively [27,29]. These results are attributed to ROS scavenging by the antioxidant defense system in mitochondria to prevent H2O2 from leaking into the cytosol. Superoxide is catalyzed to H2O2 by manganese superoxide dismutase (Mn-SOD) or copper/zinc-SOD (Cu/Zn-SOD). The mitochondrial matrix contains higher levels of Mn-SOD (1.1 × 10−5 M) compared to other compartments in a cell [30]. Approximately 90% of Cu/Zn-SOD (2.4 × 10−5 M) was found in the cytosol, and ~3% of that was found in the mitochondrial intermembrane space [30]. Superoxide generated in the mitochondrial matrix reacts with Mn-SOD, while that released into the intermembrane space or cytosol reacts with Cu/Zn-SOD. Generally, H2O2 is toxic to eukaryotic cells in the range of 0.1~1 × 10−3 M in vitro; however, such high concentrations of H2O2 are improbable under physiological conditions in vivo because H2O2 is then degraded to oxygen and water by the reaction with catalase, peroxiredoxin (Prx), or GSH peroxidase (GPx) (Figure 1).
Peroxisomes play an essential part in cellular fatty acid metabolism [31] via biochemical oxidations leading to both superoxide and H2O2 generation [32]. Peroxisomal H2O2 is metabolized mainly by catalase, a peroxisomal antioxidant [33]. One molecule of catalase can convert approximately 6 million molecules of H2O2 to oxygen and water per minute [34]. Catalase has a high Km value to H2O2, while GPx as a low one [35]. Catalase can react with H2O2 but not with other hydroperoxides, while Prx and GPx can react with both [36].
Prx and GPx have peroxidase activity in thioredoxin (Trx)- and glutaredoxin (Grx)-dependent manners, respectively [37] (Figure 1). After the reaction with H2O2, the oxidized Prx is reduced back by the reaction with Trx, while the oxidized GPx is reduced back mainly by the reaction with GSH [38]. In mammals, Trx and Grx isoforms have been characterized as cytosolic Trx1 and Grx1, and as mitochondrial Trx2 and Grx2 [37]. Trx and Grx are endogenous antioxidants that play important roles as electron donors in the cellular redox homeostasis and are also the primary reductants of disulfide bonds of intracellular proteins to protect cells against oxidative stress or apoptosis [37,39]. Subsequently, the oxidized form of Trx is reduced back by the reaction with Trx reductase (TrxR), while that of Grx is reduced back by GSH. Although GSH is then oxidized to GSSG, GSH reductase (GR) can regenerate GSH from GSSG. The reaction of GR with GSSG is regulated by nicotinamide adenine dinucleotide phosphate (NADPH), which is produced by the reaction of glucose-6-phosphate dehydrogenase with NADP+ [40]. Grx also catalyzes both the formation and reduction of glutathionylated proteins, although the latter is the main function in general [41,42]. TrxR and GR are NADPH-dependent flavoenzymes that transfer electrons to oxidized Trx and GSSG, respectively. TrxR has three isoforms: cytosolic TrxR1, mitochondrial TrxR2, and testis-specific Trx/GSH reductase [37]. It reacts not only with oxidized Trx but also with lipid hydroperoxides and H2O2 [37]. Prx is a Trx-dependent peroxidase with six isoforms, which is localized to cytosol (Prx I, II, V, and VI) mitochondria (Prx III and V), ER (Prx IV), and microsome (Prx V) [43]. Prx is kept in a reduced form as a peroxidase enzyme that receives electrons from NADPH by coupling with Trx and TrxR [44]. GPx has eight isoforms identified as selenoproteins with a selenocysteine in the catalytic center (GPx1-4 and 6) or nonselenoproteins (GPx 5, 7, and 8) [38]. Among the seleno-containing isoforms, GPx1-4 are found in mammals and GPx6 only in humans [38]. GPx1 is the predominant isoform, expressing ubiquitously in the tissues and localizing mainly to the cytosol; it is also present in the mitochondrial matrix [45], although the estimated concentration of mitochondrial GPx is lower (1.17 × 10−6 M) than that of cytosolic GPx (5.8 × 10−6 M) [29,46]. It seems that GPx is the leading H2O2 scavenger in mitochondria [29]. In this antioxidant defense system, superoxide release is undetectable in intact mitochondria [47]. However, mitochondrial dysfunction leads to increased production of both superoxide and H2O2 [48,49]. The ratio of steady state concentration of mitochondrial superoxide to H2O2, represented by [H2O2]/[superoxide], is under 100, whereas that in the cytosol is estimated to be 1,000 [29].
Considering the importance of cellular redox status, dysregulation in the redox status by GSH under pathological conditions would be involved in some human diseases such as hemolytic anemia, human immunodeficiency virus infection/acquired immune deficiency syndrome, liver disease, and cystic fibrosis [50]. Especially, GSH seems to be important in the brain because inborn errors in GSH metabolism induce neurological symptoms such as ataxia, mental retardation, seizures, spasticity, hearing loss, motor impairment or tremor etc. [51]. Moreover, several age-related neurodegenerative diseases have been involved in disorders of GSH metabolism [6]. Many lines of evidence suggest mitochondrial involvement in the pathogenesis of aging-related neurodegenerative diseases [52]. There have been reports of abnormal protein expression of Prx isoforms in the brains of neurodegenerative diseases such as Alzheimer’s disease (AD), frontotemporal dementia, Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington’s disease (HD) [53,54,55,56,57]. The Trx and Grx systems are also involved in these neurodegenerative diseases [58,59,60,61]. AD patients showed reduced blood antioxidant enzyme activities, including those of SOD, catalase, GPx, and GR [62]. GPx1 polymorphism showing a 70% decrease in enzyme activity was identified as a positive risk factor for AD [63]. Similarly, GPx activity was significantly reduced in the substantia nigra of PD patients [64]. In addition, progressive supranuclear palsy is another aging-related neurodegenerative disease showing the involvement of oxidative stress and GSH depletion in the brain [65,66]. In the CNS of progressive supranuclear palsy patients, GPx enzymatic activity is thought to be decreased by conjugation with a lipid peroxidation product, 4-hydroxy-2-nonenal [67,68]. Perturbations of cellular redox status would be closely linked to the disruption of the antioxidant systems leading to neurodegeneration.
Figure 1. Regulation of the redox homeostasis by glutathione (GSH), thioredoxin (Trx), and glutaredoxin (Grx) systems. Hydrogen peroxide (H2O2) and hydroperoxides (ROOH) are catalyzed by GSH peroxidase (GPx) or peroxiredoxin (Prx) to alcohols (ROH) and water. The oxidized form of Trx is reduced back by the reaction with Trx reductase (TrxR), while that of Grx is reduced back by GSH. An oxidized GSH (GSSG) is reduced back to two GSH molecules by the reaction of GSH reductase (GR). Both Trx and Grx reduce protein disulfides. Grx also catalyzes protein deglutathionylation.
Figure 1. Regulation of the redox homeostasis by glutathione (GSH), thioredoxin (Trx), and glutaredoxin (Grx) systems. Hydrogen peroxide (H2O2) and hydroperoxides (ROOH) are catalyzed by GSH peroxidase (GPx) or peroxiredoxin (Prx) to alcohols (ROH) and water. The oxidized form of Trx is reduced back by the reaction with Trx reductase (TrxR), while that of Grx is reduced back by GSH. An oxidized GSH (GSSG) is reduced back to two GSH molecules by the reaction of GSH reductase (GR). Both Trx and Grx reduce protein disulfides. Grx also catalyzes protein deglutathionylation.
Molecules 20 08742 g001

4. ROS/RNS Generation

Excessive ROS generation leading to oxidative stress has been implicated in the progression of some neurodegenerative diseases including AD, PD, ALS, and HD [52,69,70,71]. Especially, the production of reactive nitrogen species (RNS), which are nitric oxide (NO)-derived oxidants, has been involved in the pathogenesis of these neurodegenerative diseases [72,73,74].
NO is synthesized from L-arginine by the reaction with NO synthases (NOS) [75]. Three types of NOS have been identified: neuronal NOS (nNOS, type I), inducible NOS (iNOS, type II), and endothelial NOS (eNOS, type III) [75]. Glutamate, an excitatory neurotransmitter, activates N-methyl-d-aspartate (NMDA) receptors to open a channel permeable to Ca2+, leading to Ca2+/calmodulin-dependent activations of both nNOS and eNOS [76], but not iNOS, which is mainly regulated by NFkB activation [77]. NO can diffuse widely (~400 μm) [78] and react with superoxide to form peroxynitrite, which is a potent oxidant [73]. Peroxynitrite can damage DNA, membrane lipids, mitochondria, and proteins and induce cell death via a necrotic or apoptotic mechanism depending on production rates, endogenous antioxidant levels, and exposure time [74]. Peroxynitrite is generated at the site of superoxide production because the half-life of superoxide (10−6 s) is shorter than that of NO (~1 s) [73]. The rates of peroxynitrite production in vivo have been estimated to be as high as 50–100 μM per min [74]. The half-life of peroxynitrite is approximately 10 ms, which is enough to cross the cell membrane and influence surrounding cells at physiological pH [79,80]. No enzyme is necessary to form peroxynitrite, and the rate of superoxide reacting with NO (~1 × 1010 M−1s−1) is faster than that reacting with SOD (~2 × 109 M−1s−1) [73,74]. Basal NO levels are below 10−8 M, which is too low to effectively compete with SOD [81], although it will increase 100-fold under pathological conditions [82,83]. Furthermore, the reaction rate of superoxide and NO is elevated in a synergistic manner; i.e., the production of both superoxide and NO is increased 1,000-fold, which will increase the formation of peroxynitrite by 1,000,000-fold [74].
Many biomolecules, including tyrosine, tryptophan, guanine, cysteine, lysine, methionine and histidine residues, DNA, and fatty acids, are oxidized and/or nitrated by peroxynitrite-derived radicals [74,84]. These biological reactions induce the inhibition (and sometimes the activation) of enzymes, receptors, transporters, and membrane channels, as well as protein aggregation, impairment of cellular signaling, mitochondrial dysfunction, DNA injury, and lipid peroxidation [74,85]. Particularly in mitochondria, peroxynitrite can cause inactivation of the electron transport chain complex I, II and V, leading to superoxide and H2O2 generation [86]. Moreover, peroxynitrite can inhibit Mn-SOD activity by the nitration of a critical tyrosine-34 residue, leading to the exacerbation of mitochondrial injury [87,88]. Nitrated Mn-SOD levels were increased in the CNS of AD, PD, and ALS patients [72].
H2O2 reacts with Fe2+ (Fenton’s reaction) to form a highly oxidizing intramolecular radical, hydroxyl radical [89]. The rate constant of Fenton’s reaction is about 1.2–1.3 M−1s−1 [29], which is much slower than that of peroxynitrite formation (6.7 × 109 M−1s−1) [81]. Consequently, hydroxyl radical formation needs transition metals near a critical site to inactivate the biological target [81]. Hydroxyl radical is also produced by peroxynitrite decomposition [74,81], but this reaction is slow in biological systems [74]. Hydroxyl radical scavengers did not reduce peroxynitrite-induced cytotoxicity [90], suggesting that peroxynitrite-induced hydroxyl radical formation has a minor role in the toxicity of peroxynitrite. Hydroxyl radical can diffuse only about the diameter of a typical protein, which is limited to much less than that of peroxynitrite [81,91]. However, hydroxyl radical is a powerful oxidant, which attacks any organic molecules [81,91]. Amyloid β and α-synuclein, abnormal aggregated proteins in AD and PD, respectively, can both generate hydroxyl radical after incubation with Fe2+ in vitro [92]. Hydroxyl radical generation via Fenton’s reaction might be involved in the progression of these neurodegenerative diseases.
GSH directly reacts with superoxide, NO, peroxynitrite, and hydroxyl radical. The ability of GSH to scavenge superoxide varies among the published reports, with rate constants ranging from 102 to 105 M−1s−1 [93]. The rate constants of NO, peroxynitrite, and hydroxyl radical with GSH are ~3 × 105 M−1s−1, ~281 M−1s−1, and 1.3 × 1010 M−1s−1, respectively [93,94,95]. Considering the high intracellular concentrations, GSH acts as a potent antioxidant against a variety of ROS, while GSH depletion is caused by increased oxidative stress and/or decreased GSH synthesis, especially in neurons, which are more vulnerable to ROS than are glial cells [5].

5. Glutathione as a Regulator of Redox Signal Transduction

Protein S-glutathionylation is a reversible post-translational modification not only for protection of cysteine residues from irreversible oxidation under oxidative stress conditions but also for transduction of redox signaling by changing structure/function of various target proteins, even in intact cellular system [96,97]. Like protein phosphorylation, the S-glutathionylation modulates enzyme activities, DNA binding by transcription factors, and protein stability [17,96,98]. The modifications of protein thiols in cysteine residues can alter protein functions because many proteins contain cysteine residues in their active sites or functional motifs [99,100]. More than 2200 target sites have been identified for S-glutathionylation, which is involved in cancer migration, cell death and survival, energy metabolism and glycolysis, as well as protein folding and degradation [101,102,103]. A number of papers have been published in different diseases showing abnormal protein S-glutathionylation as a potential biomarker [17]. For more precise information regarding protein S-glutathionylation, readers are referred to other reviews [96,99,102].

6. EAAC1 Dysfunction Leading to Neurodegeneration

Excitatory amino acid transporters (EAATs) regulate glutamatergic signaling via glutamate uptake from synaptic clefts into the cells [104]. Among the five EAAT isoforms, EAAT1-3 are the most widely expressed in the brain. EAAT1 (glutamate-aspartate transporter, GLAST) and EAAT2 (glutamate transporter-1, GLT-1) are expressed in glial cells and involved mainly in synaptic glutamate clearance, while EAAT3 (excitatory amino acid carrier 1, EAAC1) is expressed in mature neurons and involved in cysteine uptake rather than in glutamate clearance in the brain. Indeed, the downexpression of GLAST or GLT-1 increased extracellular glutamate levels in the CNS, while that of EAAC1 did not affect the levels [105]. Moreover, when arginine 447, a residue conserved in all EAATs, of EAAC1 is replaced by cysteine, glutamate transport is abolished but cysteine transport remains intact [106]. Mature neurons utilize extracellular cysteine for GSH synthesis, while astrocytes utilize cystine, which is formed by oxidation of two cysteines with a disulfide bond. Intracellular cysteine levels are the rate-limiting substrate for GSH synthesis [107]. Therefore, the cysteine transport system via EAAC1 is considered key for neuronal GSH synthesis. EAAC1-deficient mice showed age-dependent brain atrophy, learning/memory dysfunction, and reduced brain GSH levels [108]. These results indicate that the cysteine transport system of EAAC1 is a notable feature, and one that is independent of the other EAATs, for neuronal GSH synthesis. However, previous studies showed that EAATs are vulnerable to oxidative stress, leading to impaired transport function by peroxynitrite or H2O2 [85]. Previous studies also have demonstrated that oxidative stress reduced neuronal cysteine uptake via EAAC1 dysfunction, leading to impaired GSH synthesis in the mouse midbrain [109]. EAAC1-deficient mice showed age-dependent loss of dopaminergic neurons in the substantia nigra and increased oxidative stress [110]. Neuronal cysteine uptake by EAAC1 was inhibited by soluble amyloid β (Aβ) oligomers in vitro [111], and aberrant EAAC1 accumulations were found in the hippocampal neurons of AD patients [112]. In an in vitro study, cysteine uptake inhibition leading to GSH depletion via EAAC1 dysfunction was found in neurons from a mouse HD model that have human huntingtin exon1 with 140 CAG repeats inserted [113]. Oxidative stress causes EAAC1 dysfunction leading to neuronal GSH depletion, which enhances oxidative stress more. Aging is considered a precipitating factor for both increased oxidative stress [114] and decreased GSH levels in the brain [115]. Brain GSH depletion is considered to precede the clinical progression of age-related neurodegenerative diseases [69,116,117]. Although further clinical evidences are still needed for elucidating the precise mechanism, it is considered plausible that EAAC1 dysfunction leading to GSH depletion is closely involved in neurodegenerative diseases.

7. Regulation of EAAC1

Redox status of sulfhydryl residues in EAAC1 affects its transport properties [118,119]. Oxidative modification of cysteine residues in EAAC1 decreased, while the reduced modification increased the glutamate transport activity [118,119]. Redox modulation of sulfhydryl residues in EAAC1 might constitute an important physiological or pathological roles in the regulation of the transport activity [118,119]. EAAC1 is also regulated at different levels related to DNA transcription, RNA translation, and protein expression on the cell surface (Figure 2). Glial EAATs, both GLAST and GLT-1, are predominantly expressed on the cell surface [120,121], while EAAC1 expresses only ~20% of the transporter on the cell surface [122]. EAAC1 is trafficked between intracellular compartments and the cell surface to change the transport activity [122,123,124]. Once stimulated by protein kinase C activation, EAAC1 expression doubles on the cell surface [122]. Phosphatidylinositol 3-kinase activation also increases cell surface expression of EAAC1, while AMP-activated protein kinase and glutamate transport-associated protein 3-18 (GTRAP3-18) inhibit EAAC1 translocation to the cell surface. RTN2B, a member of the reticulon family, enhances ER exit and the cell surface composition of EAAC1 [125]. Soluble Aβ oligomers inhibited EAAC1-mediated cysteine uptake and decreased intracellular GSH levels in vitro, even though mRNA expression of EAAC1 was reactively increased by treatment with soluble Aβ oligomers [111]. In our recent studies, GTRAP3-18-deficient mice showed increased EAAC1 expression on the cell surface, with increased neuronal GSH levels and neuroprotection against oxidative stress [126]. At forced motor/spatial learning and memory tests, GTRAP3-18-deficient mice performed better than age-matched wild-type mice [126]. The δ-opioid receptor, a G-protein coupled receptor, interacts directly with EAAC1 on the plasma membrane to reduce the glutamate transport activity [127]. For a detailed overview of this topic, we refer readers to our review articles [128,129,130]. EAAC1 protein expression is upregulated by transcriptional factors such as the nuclear factor erythroid 2-related factor 2 and the regulatory factor X1 [131,132]. The mRNA levels for EAAC1 in the rat hippocampus were upregulated after exercise [133]. On the other hand, EAAC1 protein expression is downregulated by miR-96-5p, which is a small noncoding RNA molecule, named microRNA, involved in the post-transcriptional regulation of gene expression. We have reported that cellular protection against ROS is time-dependently correlated with GSH rhythm, which is regulated by rhythmic miR-96-5p expression through the direct regulation of EAAC1 expression [134]. Upregulation of miR-96-5p decreased EAAC1 protein expression, leading to a reduction in GSH, while an miR-96-5p inhibitor increased the GSH level, leading to neuroprotection against oxidative stress via an increased level of EAAC1 [134]. The involvement of microRNA in neurodegenerative diseases is also discussed in our recent review [135]. These results indicate a potential strategy against neurodegeneration by increasing neuronal GSH via EAAC1 function.
Figure 2. Regulatory mechanisms of EAAC1, which is a neuronal transporter for cysteine (Cys) and glutamate (Glu) uptake for glutathione (GSH) synthesis. Stimulatory (arrow) and inhibitory (˫) regulations for EAAC1 activity. The abbreviations are as follows: AMP-activated protein kinase (AMPK), amyloid β (Aβ), endoplasmic reticulum (ER), excitatory amino acid carrier 1 (EAAC1), δ-opioid receptor (DOR), glutamate transport associated protein 3-18 (GTRAP3-18), nuclear factor erythroid 2-related factor 2 (Nrf2), phosphatidylinositol 3-kinase (PI3K), protein kinase C (PKC), regulatory factor X1 (RFX1).
Figure 2. Regulatory mechanisms of EAAC1, which is a neuronal transporter for cysteine (Cys) and glutamate (Glu) uptake for glutathione (GSH) synthesis. Stimulatory (arrow) and inhibitory (˫) regulations for EAAC1 activity. The abbreviations are as follows: AMP-activated protein kinase (AMPK), amyloid β (Aβ), endoplasmic reticulum (ER), excitatory amino acid carrier 1 (EAAC1), δ-opioid receptor (DOR), glutamate transport associated protein 3-18 (GTRAP3-18), nuclear factor erythroid 2-related factor 2 (Nrf2), phosphatidylinositol 3-kinase (PI3K), protein kinase C (PKC), regulatory factor X1 (RFX1).
Molecules 20 08742 g002

8. Conclusions

The intracellular redox status is determined by a balance between oxidative stress and the antioxidant system. In the brain, a consecutive imbalance toward the pro-oxidant side impairs cellular functions, leading to neurodegeneration. GSH is the most abundant thiol-containing molecule in a cell; it regulates the cellular redox condition and plays a critical role in the anti-oxidant system. GSH depletion is involved in the pathogenesis of aging-related neurodegenerative diseases. Particularly, dysfunction of EAAC1, which is a neuronal transporter for cysteine and glutamate uptake, impairs neuronal GSH synthesis to cause GSH depletion in aging-related neurodegenerative diseases. Thus, the regulation of EAAC1 is critical for neuronal GSH synthesis to maintain cellular redox homeostasis. Upregulation of EAAC1 may be a potential strategy in neurodegenerative diseases.

Acknowledgments

There was no financial support for this work.

Author Contributions

K.A. wrote the article and T.N. critically reviewed it.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Harman, D. Aging: A theory based on free radical and radiation chemistry. J. Gerontol. 1956, 11, 298–300. [Google Scholar] [CrossRef] [PubMed]
  2. Imlay, J.A. Cellular defenses against superoxide and hydrogen peroxide. Annu. Rev. Biochem. 2008, 77, 755–776. [Google Scholar] [CrossRef] [PubMed]
  3. Brosnan, J.T.; Brosnan, M.E. The sulfur-containing amino acids: An overview. J. Nutr. 2006, 136, 1636s–1640s. [Google Scholar] [PubMed]
  4. Dickinson, D.A.; Forman, H.J. Glutathione in defense and signaling: Lessons from a small thiol. Ann. N. Y. Acad. Sci. 2002, 973, 488–504. [Google Scholar] [CrossRef] [PubMed]
  5. Aoyama, K.; Watabe, M.; Nakaki, T. Regulation of neuronal glutathione synthesis. J. Pharmacol. Sci. 2008, 108, 227–238. [Google Scholar] [CrossRef] [PubMed]
  6. Aoyama, K.; Nakaki, T. Impaired glutathione synthesis in neurodegeneration. Int. J. Mol. Sci. 2013, 14, 21021–21044. [Google Scholar] [CrossRef] [PubMed]
  7. Commandeur, J.N.; Stijntjes, G.J.; Vermeulen, N.P. Enzymes and transport systems involved in the formation and disposition of glutathione S-conjugates. Role in bioactivation and detoxication mechanisms of xenobiotics. Pharmacol. Rev. 1995, 47, 271–330. [Google Scholar] [PubMed]
  8. McBean, G.J. The transsulfuration pathway: A source of cysteine for glutathione in astrocytes. Amino Acids 2012, 42, 199–205. [Google Scholar] [CrossRef] [PubMed]
  9. Schafer, F.Q.; Buettner, G.R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic. Biol. Med. 2001, 30, 1191–1212. [Google Scholar] [CrossRef] [PubMed]
  10. Gilbert, H.F. Redox control of enzyme activities by thiol/disulfide exchange. Methods Enzymol. 1984, 107, 330–351. [Google Scholar] [PubMed]
  11. Gilbert, H.F. Thiol/disulfide exchange equilibria and disulfide bond stability. Methods Enzymol. 1995, 251, 8–28. [Google Scholar] [PubMed]
  12. Poot, M.; Teubert, H.; Rabinovitch, P.S.; Kavanagh, T.J. De novo synthesis of glutathione is required for both entry into and progression through the cell cycle. J. Cell. Physiol. 1995, 163, 555–560. [Google Scholar] [CrossRef] [PubMed]
  13. Arrigo, A.P. Gene expression and the thiol redox state. Free Radic. Biol. Med. 1999, 27, 936–944. [Google Scholar] [CrossRef] [PubMed]
  14. Voehringer, D.W. Bcl-2 and glutathione: Alterations in cellular redox state that regulate apoptosis sensitivity. Free Radic. Biol. Med. 1999, 27, 945–950. [Google Scholar] [CrossRef] [PubMed]
  15. Filomeni, G.; Rotilio, G.; Ciriolo, M.R. Glutathione disulfide induces apoptosis in U937 cells by a redox-mediated p38 MAP kinase pathway. FASEB J. 2003, 17, 64–66. [Google Scholar] [PubMed]
  16. Markovic, J.; Borras, C.; Ortega, A.; Sastre, J.; Vina, J.; Pallardo, F.V. Glutathione is recruited into the nucleus in early phases of cell proliferation. J. Biol. Chem. 2007, 282, 20416–20424. [Google Scholar] [CrossRef] [PubMed]
  17. Ghezzi, P. Protein glutathionylation in health and disease. Biochim. Biophys. Acta 2013, 1830, 3165–3172. [Google Scholar] [CrossRef] [PubMed]
  18. Klatt, P.; Lamas, S. Regulation of protein function by S-glutathiolation in response to oxidative and nitrosative stress. Eur. J. Biochem. 2000, 267, 4928–4944. [Google Scholar] [CrossRef] [PubMed]
  19. Giustarini, D.; Rossi, R.; Milzani, A.; Colombo, R.; Dalle-Donne, I. S-glutathionylation: From redox regulation of protein functions to human diseases. J. Cell. Mol. Med. 2004, 8, 201–212. [Google Scholar] [CrossRef] [PubMed]
  20. Hwang, C.; Sinskey, A.J.; Lodish, H.F. Oxidized redox state of glutathione in the endoplasmic reticulum. Science 1992, 257, 1496–1502. [Google Scholar] [CrossRef] [PubMed]
  21. Bass, R.; Ruddock, L.W.; Klappa, P.; Freedman, R.B. A major fraction of endoplasmic reticulum-located glutathione is present as mixed disulfides with protein. J. Biol. Chem. 2004, 279, 5257–5262. [Google Scholar] [CrossRef] [PubMed]
  22. Banhegyi, G.; Lusini, L.; Puskas, F.; Rossi, R.; Fulceri, R.; Braun, L.; Mile, V.; di Simplicio, P.; Mandl, J.; Benedetti, A. Preferential transport of glutathione versus glutathione disulfide in rat liver microsomal vesicles. J. Biol. Chem. 1999, 274, 12213–12216. [Google Scholar] [CrossRef] [PubMed]
  23. Banhegyi, G.; Csala, M.; Nagy, G.; Sorrentino, V.; Fulceri, R.; Benedetti, A. Evidence for the transport of glutathione through ryanodine receptor channel type 1. Biochem. J. 2003, 376, 807–812. [Google Scholar] [CrossRef] [PubMed]
  24. Thannickal, V.J.; Fanburg, B.L. Reactive oxygen species in cell signaling. Am. J. Physiol. Lung Cell. Mol. Physiol. 2000, 279, L1005–L1028. [Google Scholar] [PubMed]
  25. Robertson, G.; Leclercq, I.; Farrell, G.C. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am. J. Physiol. Gastrointest. Liver Physiol. 2001, 281, G1135–G1139. [Google Scholar] [PubMed]
  26. Jezek, P.; Hlavata, L. Mitochondria in homeostasis of reactive oxygen species in cell, tissues, and organism. Int. J. Biochem. Cell Biol. 2005, 37, 2478–2503. [Google Scholar] [CrossRef] [PubMed]
  27. Chance, B.; Sies, H.; Boveris, A. Hydroperoxide metabolism in mammalian organs. Physiol. Rev. 1979, 59, 527–605. [Google Scholar] [PubMed]
  28. St-Pierre, J.; Buckingham, J.A.; Roebuck, S.J.; Brand, M.D. Topology of superoxide production from different sites in the mitochondrial electron transport chain. J. Biol. Chem. 2002, 277, 44784–44790. [Google Scholar] [CrossRef] [PubMed]
  29. Cadenas, E.; Davies, K.J. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic. Biol. Med. 2000, 29, 222–230. [Google Scholar] [CrossRef] [PubMed]
  30. Tyler, D.D. Polarographic assay and intracellular distribution of superoxide dismutase in rat liver. Biochem. J. 1975, 147, 493–504. [Google Scholar] [PubMed]
  31. Singh, I. Biochemistry of peroxisomes in health and disease. Mol. Cell. Biochem. 1997, 167, 1–29. [Google Scholar] [CrossRef] [PubMed]
  32. Antonenkov, V.D.; Grunau, S.; Ohlmeier, S.; Hiltunen, J.K. Peroxisomes are oxidative organelles. Antioxid. Redox Signal. 2010, 13, 525–537. [Google Scholar] [CrossRef] [PubMed]
  33. Giordano, C.R.; Terlecky, S.R. Peroxisomes, cell senescence, and rates of aging. Biochim. Biophys. Acta 2012, 1822, 1358–1362. [Google Scholar] [CrossRef] [PubMed]
  34. Rahman, K. Studies on free radicals, antioxidants, and co-factors. Clin. Interv. Aging 2007, 2, 219–236. [Google Scholar] [PubMed]
  35. Girotti, A.W. Lipid hydroperoxide generation, turnover, and effector action in biological systems. J. Lipid Res. 1998, 39, 1529–1542. [Google Scholar] [PubMed]
  36. Rhee, S.G.; Chae, H.Z.; Kim, K. Peroxiredoxins: A historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic. Biol. Med. 2005, 38, 1543–1552. [Google Scholar] [CrossRef] [PubMed]
  37. Ahsan, M.K.; Lekli, I.; Ray, D.; Yodoi, J.; Das, D.K. Redox regulation of cell survival by the thioredoxin superfamily: An implication of redox gene therapy in the heart. Antioxid. Redox Signal. 2009, 11, 2741–2758. [Google Scholar] [CrossRef] [PubMed]
  38. Brigelius-Flohe, R.; Maiorino, M. Glutathione peroxidases. Biochim. Biophys. Acta 2013, 1830, 3289–3303. [Google Scholar] [CrossRef] [PubMed]
  39. Ritz, D.; Beckwith, J. Roles of thiol-redox pathways in bacteria. Annu. Rev. Microbiol. 2001, 55, 21–48. [Google Scholar] [CrossRef] [PubMed]
  40. Dringen, R.; Gutterer, J.M. Glutathione reductase from bovine brain. Methods Enzymol. 2002, 348, 281–288. [Google Scholar] [PubMed]
  41. Gallogly, M.M.; Mieyal, J.J. Mechanisms of reversible protein glutathionylation in redox signaling and oxidative stress. Curr. Opin. Pharmacol. 2007, 7, 381–391. [Google Scholar] [CrossRef] [PubMed]
  42. Lillig, C.H.; Berndt, C.; Holmgren, A. Glutaredoxin systems. Biochim. Biophys. Acta 2008, 1780, 1304–1317. [Google Scholar] [CrossRef] [PubMed]
  43. Rhee, S.G.; Woo, H.A.; Kil, I.S.; Bae, S.H. Peroxiredoxin functions as a peroxidase and a regulator and sensor of local peroxides. J. Biol. Chem. 2012, 287, 4403–4410. [Google Scholar] [CrossRef] [PubMed]
  44. Arner, E.S.; Holmgren, A. Measurement of thioredoxin and thioredoxin reductase. Curr. Protoc. Toxicol. 2001, Chapter 7. Unit 7.4. [Google Scholar]
  45. Mari, M.; Morales, A.; Colell, A.; Garcia-Ruiz, C.; Fernandez-Checa, J.C. Mitochondrial glutathione, a key survival antioxidant. Antioxid. Redox Signal. 2009, 11, 2685–2700. [Google Scholar] [CrossRef] [PubMed]
  46. Stults, F.H.; Forstrom, J.W.; Chiu, D.T.; Tappel, A.L. Rat liver glutathione peroxidase: Purification and study of multiple forms. Arch. Biochem. Biophys. 1977, 183, 490–497. [Google Scholar] [CrossRef] [PubMed]
  47. Staniek, K.; Nohl, H. Are mitochondria a permanent source of reactive oxygen species? Biochim. Biophys. Acta 2000, 1460, 268–275. [Google Scholar] [CrossRef] [PubMed]
  48. Coyle, J.T.; Puttfarcken, P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993, 262, 689–695. [Google Scholar] [CrossRef] [PubMed]
  49. Turrens, J.F. Mitochondrial formation of reactive oxygen species. J. Physiol. 2003, 552, 335–344. [Google Scholar] [CrossRef] [PubMed]
  50. Townsend, D.M.; Tew, K.D.; Tapiero, H. The importance of glutathione in human disease. Biomed. Pharmacother. 2003, 57, 145–155. [Google Scholar] [CrossRef] [PubMed]
  51. Ristoff, E.; Larsson, A. Inborn errors in the metabolism of glutathione. Orphanet J. Rare Dis. 2007, 2, 16. [Google Scholar] [CrossRef] [PubMed]
  52. Lin, M.T.; Beal, M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443, 787–795. [Google Scholar] [CrossRef] [PubMed]
  53. Kim, S.H.; Fountoulakis, M.; Cairns, N.; Lubec, G. Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer’s disease and Down syndrome. J. Neural Transm. Suppl. 2001, 223–235. [Google Scholar]
  54. Krapfenbauer, K.; Engidawork, E.; Cairns, N.; Fountoulakis, M.; Lubec, G. Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res. 2003, 967, 152–160. [Google Scholar] [CrossRef] [PubMed]
  55. Kato, S.; Kato, M.; Abe, Y.; Matsumura, T.; Nishino, T.; Aoki, M.; Itoyama, Y.; Asayama, K.; Awaya, A.; Hirano, A.; et al. Redox system expression in the motor neurons in amyotrophic lateral sclerosis (ALS): Immunohistochemical studies on sporadic ALS, superoxide dismutase 1 (SOD1)-mutated familial ALS, and SOD1-mutated ALS animal models. Acta Neuropathol. 2005, 110, 101–112. [Google Scholar] [CrossRef] [PubMed]
  56. Fang, J.; Nakamura, T.; Cho, D.H.; Gu, Z.; Lipton, S.A. S-nitrosylation of peroxiredoxin 2 promotes oxidative stress-induced neuronal cell death in Parkinson’s disease. Proc. Natl. Acad. Sci. USA 2007, 104, 18742–18747. [Google Scholar] [CrossRef] [PubMed]
  57. Sorolla, M.A.; Reverter-Branchat, G.; Tamarit, J.; Ferrer, I.; Ros, J.; Cabiscol, E. Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic. Biol. Med. 2008, 45, 667–678. [Google Scholar] [CrossRef] [PubMed]
  58. Ferri, A.; Fiorenzo, P.; Nencini, M.; Cozzolino, M.; Pesaresi, M.G.; Valle, C.; Sepe, S.; Moreno, S.; Carri, M.T. Glutaredoxin 2 prevents aggregation of mutant SOD1 in mitochondria and abolishes its toxicity. Hum. Mol. Genet. 2010, 19, 4529–4542. [Google Scholar] [CrossRef] [PubMed]
  59. Sabens Liedhegner, E.A.; Gao, X.H.; Mieyal, J.J. Mechanisms of altered redox regulation in neurodegenerative diseases-focus on S-glutathionylation. Antioxid. Redox Signal. 2012, 16, 543–566. [Google Scholar] [CrossRef] [PubMed]
  60. Arodin, L.; Lamparter, H.; Karlsson, H.; Nennesmo, I.; Bjornstedt, M.; Schroder, J.; Fernandes, A.P. Alteration of thioredoxin and glutaredoxin in the progression of Alzheimer’s disease. J. Alzheimers Dis. 2014, 39, 787–797. [Google Scholar] [PubMed]
  61. Johnson, W.M.; Yao, C.; Siedlak, S.L.; Wang, W.; Zhu, X.; Caldwell, G.A.; Wilson-Delfosse, A.L.; Mieyal, J.J.; Chen, S.G. Glutaredoxin deficiency exacerbates neurodegeneration in C. elegans models of Parkinson’s disease. Hum. Mol. Genet. 2015, 24, 1322–1335. [Google Scholar] [CrossRef] [PubMed]
  62. Casado, A.; Encarnacion Lopez-Fernandez, M.; Concepcion Casado, M.; de La Torre, R. Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias. Neurochem. Res. 2008, 33, 450–458. [Google Scholar] [CrossRef] [PubMed]
  63. Paz-y-Mino, C.; Carrera, C.; Lopez-Cortes, A.; Munoz, M.J.; Cumbal, N.; Castro, B.; Cabrera, A.; Sanchez, M.E. Genetic polymorphisms in apolipoprotein e and glutathione peroxidase 1 genes in the ecuadorian population affected with Alzheimer’s disease. Am. J. Med. Sci. 2010, 340, 373–377. [Google Scholar] [CrossRef] [PubMed]
  64. Kish, S.J.; Morito, C.; Hornykiewicz, O. Glutathione peroxidase activity in Parkinson’s disease brain. Neurosci. Lett. 1985, 58, 343–346. [Google Scholar] [CrossRef] [PubMed]
  65. Albers, D.S.; Augood, S.J. New insights into progressive supranuclear palsy. Trends Neurosci. 2001, 24, 347–353. [Google Scholar] [CrossRef] [PubMed]
  66. Fitzmaurice, P.S.; Ang, L.; Guttman, M.; Rajput, A.H.; Furukawa, Y.; Kish, S.J. Nigral glutathione deficiency is not specific for idiopathic Parkinson’s disease. Mov. Disord. 2003, 18, 969–976. [Google Scholar] [CrossRef] [PubMed]
  67. Kinter, M.; Roberts, R.J. Glutathione consumption and glutathione peroxidase inactivation in fibroblast cell lines by 4-hydroxy-2-nonenal. Free Radic. Biol. Med. 1996, 21, 457–462. [Google Scholar] [CrossRef] [PubMed]
  68. Aoyama, K.; Matsubara, K.; Kobayashi, S. Aging and oxidative stress in progressive supranuclear palsy. Eur. J. Neurol. 2006, 13, 89–92. [Google Scholar] [CrossRef] [PubMed]
  69. Jenner, P. Oxidative damage in neurodegenerative disease. Lancet 1994, 344, 796–798. [Google Scholar] [CrossRef] [PubMed]
  70. Barnham, K.J.; Masters, C.L.; Bush, A.I. Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov. 2004, 3, 205–214. [Google Scholar] [CrossRef] [PubMed]
  71. Halliwell, B. Oxidative stress and neurodegeneration: Where are we now? J. Neurochem. 2006, 97, 1634–1658. [Google Scholar] [CrossRef] [PubMed]
  72. Aoyama, K.; Matsubara, K.; Fujikawa, Y.; Nagahiro, Y.; Shimizu, K.; Umegae, N.; Hayase, N.; Shiono, H.; Kobayashi, S. Nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative diseases. Ann. Neurol. 2000, 47, 524–527. [Google Scholar] [CrossRef] [PubMed]
  73. Pacher, P.; Beckman, J.S.; Liaudet, L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 2007, 87, 315–424. [Google Scholar] [CrossRef] [PubMed]
  74. Szabo, C.; Ischiropoulos, H.; Radi, R. Peroxynitrite: Biochemistry, pathophysiology and development of therapeutics. Nat. Rev. Drug Discov. 2007, 6, 662–680. [Google Scholar] [CrossRef] [PubMed]
  75. Marletta, M.A. Nitric oxide synthase: Aspects concerning structure and catalysis. Cell 1994, 78, 927–930. [Google Scholar] [CrossRef] [PubMed]
  76. Daff, S. No synthase: Structures and mechanisms. Nitric Oxide 2010, 23, 1–11. [Google Scholar] [CrossRef] [PubMed]
  77. Schroder, N.W.; Opitz, B.; Lamping, N.; Michelsen, K.S.; Zahringer, U.; Gobel, U.B.; Schumann, R.R. Involvement of lipopolysaccharide binding protein, CD14, and Toll-like receptors in the initiation of innate immune responses by Treponema glycolipids. J. Immunol. 2000, 165, 2683–2693. [Google Scholar] [CrossRef] [PubMed]
  78. Ledo, A.; Barbosa, R.M.; Gerhardt, G.A.; Cadenas, E.; Laranjinha, J. Concentration dynamics of nitric oxide in rat hippocampal subregions evoked by stimulation of the NMDA glutamate receptor. Proc. Natl. Acad. Sci. USA 2005, 102, 17483–17488. [Google Scholar] [CrossRef] [PubMed]
  79. Marla, S.S.; Lee, J.; Groves, J.T. Peroxynitrite rapidly permeates phospholipid membranes. Proc. Natl. Acad. Sci. USA 1997, 94, 14243–14248. [Google Scholar] [CrossRef] [PubMed]
  80. Denicola, A.; Souza, J.M.; Radi, R. Diffusion of peroxynitrite across erythrocyte membranes. Proc. Natl. Acad. Sci. USA 1998, 95, 3566–3571. [Google Scholar] [CrossRef] [PubMed]
  81. Beckman, J.S. Peroxynitrite versus hydroxyl radical: The role of nitric oxide in superoxide-dependent cerebral injury. Ann. N. Y. Acad. Sci. 1994, 738, 69–75. [Google Scholar] [CrossRef] [PubMed]
  82. Malinski, T.; Bailey, F.; Zhang, Z.G.; Chopp, M. Nitric oxide measured by a porphyrinic microsensor in rat brain after transient middle cerebral artery occlusion. J. Cereb. Blood Flow Metab. 1993, 13, 355–358. [Google Scholar] [CrossRef] [PubMed]
  83. Cherian, L.; Goodman, J.C.; Robertson, C.S. Brain nitric oxide changes after controlled cortical impact injury in rats. J. Neurophysiol. 2000, 83, 2171–2178. [Google Scholar] [PubMed]
  84. Torreilles, F.; Salman-Tabcheh, S.; Guerin, M.; Torreilles, J. Neurodegenerative disorders: The role of peroxynitrite. Brain Res. Rev. 1999, 30, 153–163. [Google Scholar] [CrossRef] [PubMed]
  85. Trotti, D.; Rossi, D.; Gjesdal, O.; Levy, L.M.; Racagni, G.; Danbolt, N.C.; Volterra, A. Peroxynitrite inhibits glutamate transporter subtypes. J. Biol. Chem. 1996, 271, 5976–5979. [Google Scholar] [CrossRef] [PubMed]
  86. Radi, R.; Rodriguez, M.; Castro, L.; Telleri, R. Inhibition of mitochondrial electron transport by peroxynitrite. Arch. Biochem. Biophys. 1994, 308, 89–95. [Google Scholar] [CrossRef] [PubMed]
  87. Ischiropoulos, H.; Zhu, L.; Chen, J.; Tsai, M.; Martin, J.C.; Smith, C.D.; Beckman, J.S. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch. Biochem. Biophys. 1992, 298, 431–437. [Google Scholar] [CrossRef] [PubMed]
  88. Yamakura, F.; Taka, H.; Fujimura, T.; Murayama, K. Inactivation of human manganese-superoxide dismutase by peroxynitrite is caused by exclusive nitration of tyrosine 34 to 3-nitrotyrosine. J. Biol. Chem. 1998, 273, 14085–14089. [Google Scholar] [CrossRef] [PubMed]
  89. Halliwell, B. Reactive oxygen species and the central nervous system. J. Neurochem. 1992, 59, 1609–1623. [Google Scholar] [CrossRef] [PubMed]
  90. Zhu, L.; Gunn, C.; Beckman, J.S. Bactericidal activity of peroxynitrite. Arch. Biochem. Biophys. 1992, 298, 452–457. [Google Scholar] [CrossRef] [PubMed]
  91. Hutchinson, F. The distance that a radical formed by ionizing radiation can diffuse in a yeast cell. Radiat. Res. 1957, 7, 473–483. [Google Scholar] [CrossRef] [PubMed]
  92. Tabner, B.J.; Turnbull, S.; El-Agnaf, O.M.; Allsop, D. Formation of hydrogen peroxide and hydroxyl radicals from Aβ and α-synuclein as a possible mechanism of cell death in Alzheimer’s disease and Parkinson’s disease. Free Radic. Biol. Med. 2002, 32, 1076–1083. [Google Scholar] [CrossRef] [PubMed]
  93. Jones, C.M.; Lawrence, A.; Wardman, P.; Burkitt, M.J. Electron paramagnetic resonance spin trapping investigation into the kinetics of glutathione oxidation by the superoxide radical: Re-evaluation of the rate constant. Free Radic. Biol. Med. 2002, 32, 982–990. [Google Scholar] [CrossRef] [PubMed]
  94. Kharitonov, V.G.; Sundquist, A.R.; Sharma, V.S. Kinetics of nitrosation of thiols by nitric oxide in the presence of oxygen. J. Biol. Chem. 1995, 270, 28158–28164. [Google Scholar] [CrossRef] [PubMed]
  95. Quijano, C.; Alvarez, B.; Gatti, R.M.; Augusto, O.; Radi, R. Pathways of peroxynitrite oxidation of thiol groups. Biochem. J. 1997, 322, 167–173. [Google Scholar] [PubMed]
  96. Dalle-Donne, I.; Rossi, R.; Giustarini, D.; Colombo, R.; Milzani, A. S-glutathionylation in protein redox regulation. Free Radic. Biol. Med. 2007, 43, 883–898. [Google Scholar] [CrossRef] [PubMed]
  97. Aquilano, K.; Baldelli, S.; Ciriolo, M.R. Glutathione: New roles in redox signaling for an old antioxidant. Front. Pharmacol. 2014, 5, 196. [Google Scholar] [CrossRef] [PubMed]
  98. Ghezzi, P. Regulation of protein function by glutathionylation. Free Radic. Res. 2005, 39, 573–580. [Google Scholar] [CrossRef] [PubMed]
  99. Biswas, S.; Chida, A.S.; Rahman, I. Redox modifications of protein-thiols: Emerging roles in cell signaling. Biochem. Pharmacol. 2006, 71, 551–564. [Google Scholar] [CrossRef] [PubMed]
  100. Jacob, C.; Knight, I.; Winyard, P.G. Aspects of the biological redox chemistry of cysteine: From simple redox responses to sophisticated signalling pathways. Biol. Chem. 2006, 387, 1385–1397. [Google Scholar] [CrossRef] [PubMed]
  101. Fratelli, M.; Goodwin, L.O.; Orom, U.A.; Lombardi, S.; Tonelli, R.; Mengozzi, M.; Ghezzi, P. Gene expression profiling reveals a signaling role of glutathione in redox regulation. Proc. Natl. Acad. Sci. USA 2005, 102, 13998–14003. [Google Scholar] [CrossRef] [PubMed]
  102. Pastore, A.; Piemonte, F. S-glutathionylation signaling in cell biology: Progress and prospects. Eur. J. Pharm. Sci. 2012, 46, 279–292. [Google Scholar] [CrossRef] [PubMed]
  103. Chen, Y.J.; Lu, C.T.; Lee, T.Y.; Chen, Y.J. Dbgsh: A database of S-glutathionylation. Bioinformatics 2014, 30, 2386–2388. [Google Scholar] [CrossRef] [PubMed]
  104. Danbolt, N.C. Glutamate uptake. Prog. Neurobiol. 2001, 65, 1–105. [Google Scholar] [CrossRef] [PubMed]
  105. Rothstein, J.D.; Dykes-Hoberg, M.; Pardo, C.A.; Bristol, L.A.; Jin, L.; Kuncl, R.W.; Kanai, Y.; Hediger, M.A.; Wang, Y.; Schielke, J.P.; et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996, 16, 675–686. [Google Scholar] [CrossRef] [PubMed]
  106. Bendahan, A.; Armon, A.; Madani, N.; Kavanaugh, M.P.; Kanner, B.I. Arginine 447 plays a pivotal role in substrate interactions in a neuronal glutamate transporter. J. Biol. Chem. 2000, 275, 37436–37442. [Google Scholar] [CrossRef] [PubMed]
  107. Griffith, O.W. Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic. Biol. Med. 1999, 27, 922–935. [Google Scholar] [CrossRef] [PubMed]
  108. Aoyama, K.; Suh, S.W.; Hamby, A.M.; Liu, J.; Chan, W.Y.; Chen, Y.; Swanson, R.A. Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse. Nat. Neurosci. 2006, 9, 119–126. [Google Scholar] [CrossRef] [PubMed]
  109. Aoyama, K.; Matsumura, N.; Watabe, M.; Nakaki, T. Oxidative stress on EAAC1 is involved in MPTP-induced glutathione depletion and motor dysfunction. Eur. J. Neurosci. 2008, 27, 20–30. [Google Scholar] [CrossRef] [PubMed]
  110. Berman, A.E.; Chan, W.Y.; Brennan, A.M.; Reyes, R.C.; Adler, B.L.; Suh, S.W.; Kauppinen, T.M.; Edling, Y.; Swanson, R.A. N-acetylcysteine prevents loss of dopaminergic neurons in the EAAC1−/− mouse. Ann. Neurol. 2011, 69, 509–520. [Google Scholar] [CrossRef] [PubMed]
  111. Hodgson, N.; Trivedi, M.; Muratore, C.; Li, S.; Deth, R. Soluble oligomers of amyloid-β cause changes in redox state, DNA methylation, and gene transcription by inhibiting EAAT3 mediated cysteine uptake. J. Alzheimers Dis. 2013, 36, 197–209. [Google Scholar] [PubMed]
  112. Duerson, K.; Woltjer, R.L.; Mookherjee, P.; Leverenz, J.B.; Montine, T.J.; Bird, T.D.; Pow, D.V.; Rauen, T.; Cook, D.G. Detergent-insoluble EAAC1/EAAT3 aberrantly accumulates in hippocampal neurons of Alzheimer’s disease patients. Brain Pathol. 2009, 19, 267–278. [Google Scholar] [CrossRef] [PubMed]
  113. Li, X.; Valencia, A.; Sapp, E.; Masso, N.; Alexander, J.; Reeves, P.; Kegel, K.B.; Aronin, N.; Difiglia, M. Aberrant Rab11-dependent trafficking of the neuronal glutamate transporter EAAC1 causes oxidative stress and cell death in Huntington’s disease. J. Neurosci. 2010, 30, 4552–4561. [Google Scholar] [CrossRef] [PubMed]
  114. Beckman, K.B.; Ames, B.N. The free radical theory of aging matures. Physiol. Rev. 1998, 78, 547–581. [Google Scholar] [PubMed]
  115. Maher, P. The effects of stress and aging on glutathione metabolism. Ageing Res. Rev. 2005, 4, 288–314. [Google Scholar] [CrossRef] [PubMed]
  116. Jenner, P. Oxidative stress in Parkinson’s disease. Ann. Neurol. 2003, 53, S26–S38. [Google Scholar] [CrossRef] [PubMed]
  117. Sultana, R.; Piroddi, M.; Galli, F.; Butterfield, D.A. Protein levels and activity of some antioxidant enzymes in hippocampus of subjects with amnestic mild cognitive impairment. Neurochem. Res. 2008, 33, 2540–2546. [Google Scholar] [CrossRef] [PubMed]
  118. Trotti, D.; Rizzini, B.L.; Rossi, D.; Haugeto, O.; Racagni, G.; Danbolt, N.C.; Volterra, A. Neuronal and glial glutamate transporters possess an SH-based redox regulatory mechanism. Eur. J. Neurosci. 1997, 9, 1236–1243. [Google Scholar] [CrossRef] [PubMed]
  119. Trotti, D.; Nussberger, S.; Volterra, A.; Hediger, M.A. Differential modulation of the uptake currents by redox interconversion of cysteine residues in the human neuronal glutamate transporter EAAC1. Eur. J. Neurosci. 1997, 9, 2207–2212. [Google Scholar] [CrossRef] [PubMed]
  120. Duan, S.; Anderson, C.M.; Stein, B.A.; Swanson, R.A. Glutamate induces rapid upregulation of astrocyte glutamate transport and cell-surface expression of GLAST. J. Neurosci. 1999, 19, 10193–10200. [Google Scholar] [PubMed]
  121. Kalandadze, A.; Wu, Y.; Fournier, K.; Robinson, M.B. Identification of motifs involved in endoplasmic reticulum retention-forward trafficking of the GLT-1 subtype of glutamate transporter. J. Neurosci. 2004, 24, 5183–5192. [Google Scholar] [CrossRef] [PubMed]
  122. Fournier, K.M.; Gonzalez, M.I.; Robinson, M.B. Rapid trafficking of the neuronal glutamate transporter, EAAC1: Evidence for distinct trafficking pathways differentially regulated by protein kinase C and platelet-derived growth factor. J. Biol. Chem. 2004, 279, 34505–34513. [Google Scholar] [CrossRef] [PubMed]
  123. Gonzalez, M.I.; Krizman-Genda, E.; Robinson, M.B. Caveolin-1 regulates the delivery and endocytosis of the glutamate transporter, excitatory amino acid carrier 1. J. Biol. Chem. 2007, 282, 29855–29865. [Google Scholar] [CrossRef] [PubMed]
  124. Gonzalez, M.I.; Susarla, B.T.; Fournier, K.M.; Sheldon, A.L.; Robinson, M.B. Constitutive endocytosis and recycling of the neuronal glutamate transporter, excitatory amino acid carrier 1. J. Neurochem. 2007, 103, 1917–1931. [Google Scholar] [CrossRef] [PubMed]
  125. Liu, Y.; Vidensky, S.; Ruggiero, A.M.; Maier, S.; Sitte, H.H.; Rothstein, J.D. Reticulon RTN2B regulates trafficking and function of neuronal glutamate transporter EAAC1. J. Biol. Chem. 2008, 283, 6561–6571. [Google Scholar] [CrossRef] [PubMed]
  126. Aoyama, K.; Wang, F.; Matsumura, N.; Kiyonari, H.; Shioi, G.; Tanaka, K.; Kinoshita, C.; Kikuchi-Utsumi, K.; Watabe, M.; Nakaki, T. Increased neuronal glutathione and neuroprotection in GTRAP3-18-deficient mice. Neurobiol. Dis. 2012, 45, 973–982. [Google Scholar] [CrossRef] [PubMed]
  127. Xia, P.; Pei, G.; Schwarz, W. Regulation of the glutamate transporter EAAC1 by expression and activation of δ-opioid receptor. Eur. J. Neurosci. 2006, 24, 87–93. [Google Scholar] [CrossRef] [PubMed]
  128. Aoyama, K.; Watabe, M.; Nakaki, T. Modulation of neuronal glutathione synthesis by EAAC1 and its interacting protein GTRAP3-18. Amino Acids 2012, 42, 163–169. [Google Scholar] [CrossRef] [PubMed]
  129. Aoyama, K.; Nakaki, T. Inhibition of GTRAP3-18 may increase neuroprotective glutathione (GSH) synthesis. Int. J. Mol. Sci. 2012, 13, 12017–12035. [Google Scholar] [CrossRef] [PubMed]
  130. Aoyama, K.; Nakaki, T. Neuroprotective properties of the excitatory amino acid carrier 1 (EAAC1). Amino Acids 2013, 45, 133–142. [Google Scholar] [CrossRef] [PubMed]
  131. Ma, K.; Zheng, S.; Zuo, Z. The transcription factor regulatory factor X1 increases the expression of neuronal glutamate transporter type 3. J. Biol. Chem. 2006, 281, 21250–21255. [Google Scholar] [CrossRef] [PubMed]
  132. Escartin, C.; Joon Won, S.; Malgorn, C.; Auregan, G.; Berman, A.E.; Chen, P.C.; Deglon, N.; Johnson, J.A.; Won Suh, S.; Swanson, R.A. Nuclear factor erythroid 2-related factor 2 facilitates neuronal glutathione synthesis by upregulating neuronal excitatory amino acid transporter 3 expression. J. Neurosci. 2011, 31, 7392–7401. [Google Scholar] [CrossRef] [PubMed]
  133. Molteni, R.; Ying, Z.; Gomez-Pinilla, F. Differential effects of acute and chronic exercise on plasticity-related genes in the rat hippocampus revealed by microarray. Eur. J. Neurosci. 2002, 16, 1107–1116. [Google Scholar] [CrossRef] [PubMed]
  134. Kinoshita, C.; Aoyama, K.; Matsumura, N.; Kikuchi-Utsumi, K.; Watabe, M.; Nakaki, T. Rhythmic oscillations of the microRNA miR-96-5p play a neuroprotective role by indirectly regulating glutathione levels. Nat. Commun. 2014, 5, 3823. [Google Scholar] [CrossRef] [PubMed]
  135. Kinoshita, C.; Aoyama, K.; Nakaki, T. microRNA as a new agent for regulating neuronal glutathione synthesis and metabolism. AIMS Mol. Sci. 2015, 2, 124–143. [Google Scholar] [CrossRef]

Share and Cite

MDPI and ACS Style

Aoyama, K.; Nakaki, T. Glutathione in Cellular Redox Homeostasis: Association with the Excitatory Amino Acid Carrier 1 (EAAC1). Molecules 2015, 20, 8742-8758. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules20058742

AMA Style

Aoyama K, Nakaki T. Glutathione in Cellular Redox Homeostasis: Association with the Excitatory Amino Acid Carrier 1 (EAAC1). Molecules. 2015; 20(5):8742-8758. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules20058742

Chicago/Turabian Style

Aoyama, Koji, and Toshio Nakaki. 2015. "Glutathione in Cellular Redox Homeostasis: Association with the Excitatory Amino Acid Carrier 1 (EAAC1)" Molecules 20, no. 5: 8742-8758. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules20058742

Article Metrics

Back to TopTop